CYP2D6 is a critical pharmacogenetic target, and polymorphisms in the gene region are commonly used to infer enzyme activity score and predict resulting metabolizer phenotype: poor, intermediate, extensive/normal, or ultrarapid which can be useful in determining cause and/or manner of death in some...
No difference was observed in the prevalence of CYP2D6 phenotypes (poor metabolizer, intermediate metabolizer, extensive metabolizer and ultrarapid metabolizer) between the ECT and the control patients (5.3, 38.7, 56.0 and 0.0% vs. 6.4, 51.0, 42.6 and 0.0%, respectively). The types of ...
Twitter Google Share on Facebook poor metabolizer Pharmacology A person who metabolizes a probe drug–the rate of which is related to the metabolizing cytochrome P-450 enzyme–slower than others; a person can be a PM of one probe drug, and an extensive metabolizer of another. See Probe drug...
Methods: Baseline and follow-up mammograms were retrieved for 278 tamoxifen-treated subjects with CYP2D6 metabolizer status (extensive (EM), heterozygous extensive/intermediate (hetEM/IM) or poor metabolizer (PM)). Logistic regression analyses were conducted comparing subjects who experienced > 10% ...
No difference was observed in the prevalence of CYP2D6 phenotypes (poor metabolizer, intermediate metabolizer, extensive metabolizer and ultrarapid metabolizer) between the ECT and the control patients (5.3, 38.7, 56.0 and 0.0% vs. 6.4, 51.0, 42.6 and 0.0%, respectively). The types of ...
CYP2D6pharmacogenomicsCytochrome p450 family 2, subfamily D, polypeptide 6 (CYP2D6) may be used to infer the metabolizer phenotype (MP) of an individual as poor, intermediate, extensive/normal, or ultra-rapid. MPs may suggest idiosyncratic drug responses as contributing factors to cause ...
The variant CYP2D6 alleles can be classified into categories, which cause abolished, decreased, normal, increased or qualitatively altered catalytic activity [1]. Accordingly, the polymorphism of the enzyme results in poor, intermediate, extensive or ultrarapid metabolizers of CYP2D6 drugs. The ...
A linear gene-dose effect of the number of active CYP2D6 genes was detected for E-doxepin with AUCs of 235, 424, 1058, and 2730 nmol 路 h路 L-1 in ultrafast, extensive, intermediate, and poor metabolizers. 5-HT concentrations in platelets showed a significant trend towards higher ...
RESULTS: In the prospective study, comprising one poor and nine extensive/intermediate metabolizers, the apparent oral clearance (CL/F) of both enantiomers increased with the number of functional CYP2D6 genes. In the nine extensive/intermediate metabolizers receiving the 100 mg/day dose,...
Discussion Our findings provide preliminary support to the earlier observation of association of poor and intermediate metabolizer status of CYP2D6 with AIM. This is presumably because the drug has more time to build up in the system of those who are poor or intermediate metabolizers than extensive...